Document ID: chunk:federal_register_of_legislation:F2022C00912:reg:9:p3
Version: federal_register_of_legislation:F2022C00912
Segment Type: reg
Provision Reference: reg 9 (pt 3/3)
Character Range: 10183–11641

drugs within the three months before the clinical onset of deep vein thrombosis;
            Note: specified list of drugs is defined in the Schedule 1 - Dictionary.
(29)      taking combined estrogen-progestogen contraception or taking menopausal hormone therapy as an oral estrogen, or a non-oral estrogen combined with a progestogen, for a continuous period of at least four weeks, within the three months before the clinical onset of deep vein thrombosis;
            Note: menopausal hormone therapy is defined in the Schedule 1 - Dictionary.
(30)      having smoked tobacco products:
(a)          in an amount of at least one pack-year before the clinical onset of deep vein thrombosis; or
(b)          in an amount of at least 10 cigarettes per day, or the equivalent thereof in other tobacco products, for a period of at least three months before the clinical onset of deep vein thrombosis; and
         if smoking has ceased before the clinical onset of deep vein thrombosis, then that onset occurred within six months of cessation;
            Note: cigarettes per day, or the equivalent thereof in other tobacco products and one pack-year are defined in the Schedule 1 - Dictionary.
(31)      being at an altitude of at least 3,000 metres for a continuous period of at least five days within the three months before the clinical onset of deep vein thrombosis;
(32)      inability to obtain appropriate clinical management for deep vein thrombosis.